• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

United Therapeutics touts study results for inhaled Tyvaso treatment

June 30, 2021 By Sean Whooley

Tyvaso United Therapeutics
[Image from United Therapeutics]
United Therapeutics (NSDQ:UTHR) today announced positive results from an analysis of forced vital capacity (FVC) change with its Tyvaso treatment.

Research Triangle Park, N.C.–based United Therapeutics developed Tyvaso (treprostinil) as an inhalation solution for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA approved the treatment in April 2020.

The posthoc analysis of FVC change in patients during the Increase study of Tyvaso was published in The Lancet Respiratory Medicine. The analysis demonstrated that inhaled treprostinil was associated with improvements in FVC compared to placebo over 16 weeks, with improvements most evident in patients with idiopathic pulmonary fibrosis (IPF), according to a news release.

United Therapeutics said the analysis, combined with literature demonstrating the in vitro antifibrotic effects of treprostinil, offer the basis for the pivotal Teton study of Tyvaso in patients with IPF.

Positive data from the posthoc analysis adds to the reported data from the Increase trial that led to FDA approval, which met its primary endpoint (demonstration of a significant improvement in six-minute walk distance) and observed improvements in each of the secondary endpoints, including a reduction in the cardiac biomarker NT-proBNP, time to first clinical worsening event, change in peak six-minute walk distance at week 12 and change in trough six-minute walk distance at week 15.

“Patients with IPF have generally used two therapies that modestly slow the progression of their disease but come with challenging side effects that can make treatment difficult,” United Therapeutics CMO Gil Golden said in the release. “This analysis is exciting because rather than slowing down the rate of FVC deterioration, Tyvaso actually improved FVC in the relatively short 16-week duration of the Increase study.

“If the Teton study supports eventual approval of Tyvaso in patients with IPF, we look forward to providing a new treatment option for these patients with few current treatment options for this life-threatening medical condition.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: United Therapeutics

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS